3-methyl-1-(2-(4-propyl-2H-1-benzopyran-2-on-7-yloxy)acetyl)-1,2-dihydropyrazol-5-one | 1246440-67-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 3-methyl-1-(2-(4-propyl-2H-1-benzopyran-2-on-7-yloxy)acetyl)-1,2-dihydropyrazol-5-one
• 英文别名: 5-methyl-2-[2-(2-oxo-4-propylchromen-7-yl)oxyacetyl]-1H-pyrazol-3-one
• CAS: 1246440-67-4
• 化学式: C₁₈H₁₈N₂O₅
• 分子量: 342.351
• InChiKey: XDRXMIKEUJBWSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  84.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-[(oxo-4-propyl-2H-chromen-7-yl)oxy]ethanohydrazide 、 乙酰乙酸乙酯 在 溶剂黄146 作用下， 反应 6.0h， 以90%的产率得到3-methyl-1-(2-(4-propyl-2H-1-benzopyran-2-on-7-yloxy)acetyl)-1,2-dihydropyrazol-5-one
  参考文献：
  名称：

  Synthesis and docking studies of novel benzopyran-2-ones with anticancer activity

  摘要：

  Novel series of 7-substituted-benzopyran-2-ones was synthesized by incorporating heterocyclic rings as oxadiazole, triazole, pyrazole or pyrazolin-5-one to benzopyran-2-one nucleus at p-7 via methylene-oxy or acetoxy linker. In-vitro anticancer activity was evaluated for these hybrids; twelve compounds were selected by National Cancer Institute for anticancer screening. Among them, compound 9a exhibited broad spectrum antitumor activity showing full panel median growth inhibition (GI(50)) = 5.46 mu M. According to docking results using Molsoft ICM 3.4-8c program, the target compounds may act through inhibition of topoismerase 1, where camptothecin is used as ligand. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.05.050

文献信息

• Synthesis and docking studies of novel benzopyran-2-ones with anticancer activity
  作者：Magda M.F. Ismail、Heba S. Rateb、Mohammad M.M. Hussein

  DOI：10.1016/j.ejmech.2010.05.050

  日期：2010.9

  Novel series of 7-substituted-benzopyran-2-ones was synthesized by incorporating heterocyclic rings as oxadiazole, triazole, pyrazole or pyrazolin-5-one to benzopyran-2-one nucleus at p-7 via methylene-oxy or acetoxy linker. In-vitro anticancer activity was evaluated for these hybrids; twelve compounds were selected by National Cancer Institute for anticancer screening. Among them, compound 9a exhibited broad spectrum antitumor activity showing full panel median growth inhibition (GI(50)) = 5.46 mu M. According to docking results using Molsoft ICM 3.4-8c program, the target compounds may act through inhibition of topoismerase 1, where camptothecin is used as ligand. (C) 2010 Elsevier Masson SAS. All rights reserved.